Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

121.22 -2.37 (-1.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 15, 2023: TSLA, SRPT, TJX, MNDY, LTRY
Tesla (TSLA) - The company will host its annual shareholder meeting on Tuesday. The event will be broadcast on YouTube and begins at 4 p.m. EDT. A reminder that annual shareholder meetings are 
Via Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher Monday after the company announced the FDA voted in favor of its gene therapy to treat Duchenne muscular dystrophy late... 
Via Benzinga
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene... 
Via Benzinga
2 Supercharged Growth Stocks to Buy Right Now
These two biopharma stocks might be poised for a major breakout. 
Via The Motley Fool
Why Sarepta Therapeutics Stock Faded This Week
The biotech's shares have turned volatile ahead of an important regulatory event. 
Via The Motley Fool
Sarepta: The AdCom Documents Enter The Discussion
The AdCom documents are going to stimulate a robust discussion about the upcoming vote. 
Via Talk Markets
Expert Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics Earnings Preview
Via Benzinga
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy
The gene therapy would treat Duchenne muscular dystrophy, a muscle-wasting disease. 
Via Investor's Business Daily
FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee is meeting this Friday to discuss Sarepta Therapeutics Inc's (NASDAQ: SRPT) to review SRP-9001 (delandistrogene moxeparvovec),... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta: More Drama Or Just More Noise?
Sarepta has a history at the FDA and recent reports indicate additional issues. What are the implications for accelerated approval and the long term prospects of Sarepta? 
Via Talk Markets
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness
Via Benzinga
FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy
Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy. 
Via Benzinga
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
According to a report, some staffers wanted to reject the highly watched drug. 
Via Investor's Business Daily
Why Is Merck (MRK) Stock Up Today?
Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda. 
Via InvestorPlace
Why Is BigBear.ai (BBAI) Stock Down 5% Today?
BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. 
Via InvestorPlace
Why Sarepta Therapeutics Stock Is Tumbling Today
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.